Journalartikel

Jahr der Veröffentlichung: 2021

Seiten: 31-53

Zeitschrift: British Journal of Pharmacology

Bandnummer: 178

Heftnummer: 1

ISSN: 0007-1188

eISSN: 1476-5381

Open Access Status: Hybrid

DOI Link: https://doi.org/10.1111/bph.14919

Verlag: Wiley

Abstract: 
Pulmonary hypertension (PH) is a progressive pulmonary vasculopathy that causes chronic right ventricular pressure overload and often leads to right ventricular failure. Various kinase inhibitors have been studied in the setting of PH and either improved or worsened the disease, highlighting the importance of understanding the specific role of the respective kinases in a spatiotemporal cellular context. In this review, we will summarize the knowledge on the role of kinases in PH and focus on druggable targets for which certain criteria are met: (a) deregulation of the kinase in PH; (b) small-molecule inhibitors are available (e.g. from the oncology field); (c) preclinical studies have shown their efficacy in PH models; and (d) when available, therapeutic exploitation in human PH has been initiated. Along this line, clinical considerations such as personalized medicine approaches to predict therapy response and adverse side events such as cardiotoxicity together with their clinical management are discussed.

Harvard-Zitierstil: Weiss, A., Boehm, M., Egemnazarov, B., Grimminger, F., Pullamsetti, S., Kwapiszewska, G., et al. (2021) Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction, British Journal of Pharmacology, 178(1), pp. 31-53. https://doi.org/10.1111/bph.14919

APA-Zitierstil: Weiss, A., Boehm, M., Egemnazarov, B., Grimminger, F., Pullamsetti, S., Kwapiszewska, G., & Schermuly, R. (2021). Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction. British Journal of Pharmacology. 178(1), 31-53. https://doi.org/10.1111/bph.14919